Get started
Author

Melanie K. Saville

Observed names: M. Saville, Melanie Saville, Mélanie Saville
Observed institutions: Program for Appropriate Technology in Health, Stavanger University Hospital, Sanofi (France), Coalition for Epidemic Preparedness Innovations, St Mary's Hospital, Coalition for Epidemic Preparedness Innovations, Wyeth, University College London
ORCID: 0000-0002-3032-0596
Observed ORCID: 0000-0002-3032-0596
OpenAlex ID: A5048822204
The COVID-19 vaccine development landscape
2020 · Tung Thanh Le, Zacharias Andreadakis, et al. · Nature Reviews Drug Discovery · 1,956
Developing Covid-19 Vaccines at Pandemic Speed
2020 · Nicole Lurie, Melanie Saville, et al. · New England Journal of Medicine · 1,557
Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease
2015 · Sri Rezeki Hadinegoro, Jose Luis Arredondo-García, et al. · New England Journal of Medicine · 1,079
PDF
Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial
2014 · Maria Rosario Capeding, Ngoc Huu Tran, et al. · The Lancet · 975
Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America
2014 · Luis Villar, Gustavo Horacio Dayan, et al. · New England Journal of Medicine · 943
PDF
Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial
2012 · Arunee Sabchareon, Derek Wallace, et al. · The Lancet · 818
Vaccine development for emerging infectious diseases
2021 · Jean-Louis Excler, Melanie Saville, et al. · Nature Medicine · 411
PDF
Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial
2006 · Jean-Louis Bresson, Christian Perronne, et al. · The Lancet · 411
From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine
2011 · Bruno Guy, Beatrice Barrere, et al. · Vaccine · 322
Multiplex PCR for Typing and Subtyping Influenza and Respiratory Syncytial Viruses
1998 · J. Stockton, J. S. Ellis, et al. · Journal of Clinical Microbiology · 316
PDF
Comparison of the Efficacy and Safety of Live Attenuated Cold-Adapted Influenza Vaccine, Trivalent, With Trivalent Inactivated Influenza Virus Vaccine in Children and Adolescents With Asthma
2006 · Douglas M. Fleming, Pietro Crovari, et al. · The Pediatric Infectious Disease Journal · 272
Intradermal Influenza Vaccine Administered Using a New Microinjection System Produces Superior Immunogenicity in Elderly Adults: A Randomized Controlled Trial
2008 · David Holland, Robert Booy, et al. · The Journal of Infectious Diseases · 254
PDF
Safety, Efficacy, and Effectiveness of Cold-Adapted Influenza Vaccine-Trivalent Against Community-Acquired, Culture-Confirmed Influenza in Young Children Attending Day Care
2006 · Timo Vesikari, Douglas M. Fleming, et al. · PEDIATRICS · 180
Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward
2015 · Bruno Guy, Olivier Briand, et al. · Vaccine · 173
PDF
A phase I clinical trial of a PER.C6® cell grown influenza H7 virus vaccine
2009 · Rebecca J. Cox, Abdullah S. Madhun, et al. · Vaccine · 140
A Randomized, Double-Blind Study of the Safety, Transmissibility and Phenotypic and Genotypic Stability of Cold-Adapted Influenza Virus Vaccine
2006 · Timo Vesikari, Aino Karvonen, et al. · The Pediatric Infectious Disease Journal · 129
Development of sanofi pasteur tetravalent dengue vaccine
2010 · Bruno Guy, Melanie Saville, et al. · Human Vaccines · 126
PDF
Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults
2013 · Stéphanie Pépin, Yves Donazzolo, et al. · Vaccine · 100
Delivering Pandemic Vaccines in 100 Days — What Will It Take?
2022 · Melanie Saville, Jakob P. Cramer, et al. · New England Journal of Medicine · 92
PDF
Immunogenicity and safety of tetravalent dengue vaccine in 2–11 year-olds previously vaccinated against yellow fever: Randomized, controlled, phase II study in Piura, Peru
2012 · Claudio F. Lanata, Teresa Andrade, et al. · Vaccine · 74
Factors, enablers and challenges for COVID-19 vaccine development
2023 · Jean-Louis Excler, Melanie Saville, et al. · BMJ Global Health · 67
PDF
A review of Lassa fever vaccine candidates
2019 · Kolawole Salami, Dimitrios Gouglas, et al. · Current Opinion in Virology · 63
Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials
2016 · Sophia Gailhardou, Anna Skipetrova, et al. · PLoS neglected tropical diseases · 56
PDF
Vaccination Against Dengue: Challenges and Current Developments
2015 · Bruno Guy, Jean Lang, et al. · Annual Review of Medicine · 53
Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial
2015 · Josefina B. Cadorna-Carlos, Terry Nolan, et al. · Vaccine · 50
Works count: 58
Citation count: 11,050
H-index: 30
I10-index: 43
Year
Topic
Type